Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1994 Apr;53(4):235–239. doi: 10.1136/ard.53.4.235

Changes in levels of soluble T-cell activation markers, sIL-2R, sCD4 and sCD8, in relation to disease exacerbations in patients with systemic lupus erythematosus: a prospective study.

P E Spronk 1, E J ter Borg 1, M G Huitema 1, P C Limburg 1, C G Kallenberg 1
PMCID: PMC1005301  PMID: 8203951

Abstract

OBJECTIVES--To assess serial activation of T-cell subsets in relation to auto-antibody production and the occurrence of disease exacerbations in patients with systemic lupus erythematosus (SLE). METHODS--To study the possible role of T-cells in the pathophysiology of the disease, 16 consecutive exacerbations were prospectively studied in a cohort of patients with SLE, and serial plasma levels of sIL-2R, sCD4, and sCD8 preceding and during these exacerbations were determined. Levels of these molecules were related to total IgM and IgG, and anti-dsDNA. RESULTS--During major disease exacerbations (n = 6), levels of sIL-2R increased significantly (p < 0.001). Levels of sCD4 were predominantly in the normal range, whereas levels of sCD8 were frequently increased. No change in levels of both molecules could be detected in the period before the exacerbation. During minor exacerbations (n = 10), levels of sIL-2R remained stable. Levels of sCD4, however, tended to drop, whereas levels of sCD8 tended to rise. No correlations were found between sIL-2R, sCD4 or sCD8 on the one hand, and total IgM, IgG, or anti-dsDNA on the other. CONCLUSIONS--Levels of sIL-2R are increased, and rise before major exacerbations of SLE. Levels of sCD4 and sCD8, however, are not related to levels of sIL-2R, and do not reflect B-cell activation, nor disease activity during exacerbations of SLE. Thus for the clinical follow up of SLE measurement of levels of sCD4 or sCD8 is of limited value.

Full text

PDF
239

Images in this article

237Image
on p.237

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Becker H., Paul E., Schaum S., Renelt M., Federlin K. Zirkulierendes CD8 als Aktivitätsparameter bei entzündlich-rheumatischen Erkrankungen. Immun Infekt. 1992 Feb;20(1):6–9. [PubMed] [Google Scholar]
  2. Carpenter A. B., Eisenbeis C. H., Jr, Carrabis S., Brown M. C., Ip S. H. Elevated soluble CD8 in the synovial fluid from patients with rheumatoid arthritis. J Clin Lab Anal. 1990;4(5):337–341. doi: 10.1002/jcla.1860040505. [DOI] [PubMed] [Google Scholar]
  3. Carteron N. L., Schimenti C. L., Wofsy D. Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion. J Immunol. 1989 Mar 1;142(5):1470–1475. [PubMed] [Google Scholar]
  4. Donati D., Degiannis D., Homer L., Gastaldi L., Raskova J., Raska K., Jr Immune deficiency in uremia: interleukin-2 production and responsiveness and interleukin-2 receptor expression and release. Nephron. 1991;58(3):268–275. doi: 10.1159/000186435. [DOI] [PubMed] [Google Scholar]
  5. Famularo G., Giacomelli R., Sacchetti S., Danese C., Luciani A. M., Perego M. A., Tonietti G. Soluble CD8 antigen in systemic sclerosis. J Clin Lab Immunol. 1990 Jul;32(3):109–112. [PubMed] [Google Scholar]
  6. Feltkamp T. E., Kirkwood T. B., Maini R. N., Aarden L. A. The first international standard for antibodies to double stranded DNA. Ann Rheum Dis. 1988 Sep;47(9):740–746. doi: 10.1136/ard.47.9.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Furukawa S., Matsubara T., Tsuji K., Motohashi T., Okumura K., Yabuta K. Serum soluble CD4 and CD8 levels in Kawasaki disease. Clin Exp Immunol. 1991 Oct;86(1):134–139. doi: 10.1111/j.1365-2249.1991.tb05785.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Groen H., Aslander M., Bootsma H., van der Mark T. W., Kallenberg C. G., Postma D. S. Bronchoalveolar lavage cell analysis and lung function impairment in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1993 Oct;94(1):127–133. doi: 10.1111/j.1365-2249.1993.tb05989.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Munves E. F., Schur P. H. Antibodies to Sm and RNP. Prognosticators of disease involvement. Arthritis Rheum. 1983 Jul;26(7):848–853. doi: 10.1002/art.1780260705. [DOI] [PubMed] [Google Scholar]
  10. Rubin L. A., Kurman C. C., Fritz M. E., Biddison W. E., Boutin B., Yarchoan R., Nelson D. L. Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985 Nov;135(5):3172–3177. [PubMed] [Google Scholar]
  11. Sawada S., Sugai S., Iijima S., Takei M., Paredes E., Hayama T., Nishinarita S., Hosokawa Y., Horie T., Obara T. Increased soluble CD4 and decreased soluble CD8 molecules in patients with Sjögren's syndrome. Am J Med. 1992 Feb;92(2):134–140. doi: 10.1016/0002-9343(92)90103-i. [DOI] [PubMed] [Google Scholar]
  12. Spronk P. E., ter Borg E. J., Limburg P. C., Kallenberg C. G. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity? Clin Exp Immunol. 1992 Oct;90(1):106–110. doi: 10.1111/j.1365-2249.1992.tb05840.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Spronk P. E., vd Gun B. T., Limburg P. C., Kallenberg C. G. B cell activation in clinically quiescent systemic lupus erythematosus (SLE) is related to immunoglobulin levels, but not to levels of anti-dsDNA, nor to concurrent T cell activation. Clin Exp Immunol. 1993 Jul;93(1):39–44. doi: 10.1111/j.1365-2249.1993.tb06494.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Stegeman C. A., Tervaert J. W., Huitema M. G., Kallenberg C. G. Serum markers of T cell activation in relapses of Wegener's granulomatosis. Clin Exp Immunol. 1993 Mar;91(3):415–420. doi: 10.1111/j.1365-2249.1993.tb05918.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Symons J. A., Wood N. C., di Giovine F. S., Duff G. W. Soluble CD8 in patients with rheumatic diseases. Clin Exp Immunol. 1990 Jun;80(3):354–359. doi: 10.1111/j.1365-2249.1990.tb03292.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Tan E. M., Cohen A. S., Fries J. F., Masi A. T., McShane D. J., Rothfield N. F., Schaller J. G., Talal N., Winchester R. J. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 Nov;25(11):1271–1277. doi: 10.1002/art.1780251101. [DOI] [PubMed] [Google Scholar]
  17. ter Borg E. J., Horst G., Hummel E. J., Limburg P. C., Kallenberg C. G. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum. 1990 May;33(5):634–643. doi: 10.1002/art.1780330505. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES